| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
The molecular targets of Cyclocurcumin are not fully characterized in the provided literature. As a curcuminoid, it is believed to interact with multiple cellular targets involved in inflammation, oxidative stress, and cancer pathways. Curcuminoids are known to modulate various signaling pathways, including NF-κB, STAT3, and MAPK pathways, and to interact with enzymes such as cyclooxygenases and lipoxygenases. Cyclocurcumin's distinct structure may confer unique target interactions and bioactivities compared to curcumin.
|
|---|---|
| ln Vitro |
In LPS-stimulated human macrophages, cyclocurcumin (10–40 μM; 18 h) significantly reduces TNF-α release in a dose-dependent manner [1]. Freshly isolated rat aorta is exposed to cyclocurcumin (5-25 μM) which causes concentration-dependent vasoconstriction triggered by cyclophenylephrine (IC50=14.9±1.0 μM)[2]. In a dose-dependent manner, cyclocurcumin (5-25 μM; 30 min) suppresses intracellular calcium influx. Vasoconstriction mediated by L-type calcium channels is inhibited by cyclocurcumin in a concentration-dependent manner. Cyclocurcumin's anti-contractile action is reversible [2]. Strong scavenging activity against \OH and \OOH free radicals is exhibited by cyclocurcumin, and in physiological and aqueous settings, its 4'-OH phenol radicals preferentially scavenge \OH and \OOH free radicals via the process of atom transfer [3].
Cyclocurcumin has been studied for its potent anti-inflammatory, antioxidant, and anticancer properties. It is believed to be more stable than curcumin, making it a promising candidate for therapeutic applications. The compound's activity is likely related to its ability to modulate inflammatory mediators, scavenge free radicals, and inhibit cancer cell proliferation. Specific in vitro activity data, such as IC50 values, is not detailed in the provided literature. |
| ln Vivo |
In vivo, Cyclocurcumin may offer benefits in treating diseases associated with inflammation, oxidative stress, and cancer. Its potential advantages over curcumin, such as greater stability, could translate to improved bioavailability and therapeutic efficacy. However, specific in vivo data for Cyclocurcumin is not detailed in the provided literature. Further studies are needed to fully characterize its pharmacokinetic and pharmacodynamic properties.
|
| Enzyme Assay |
In vitro binding and enzyme activity assays for Cyclocurcumin would typically involve measuring its ability to modulate inflammatory and antioxidant pathways. These assays could include testing against inflammatory enzymes (COX, LOX), kinases (e.g., IKK, MAPK), or transcription factors (e.g., NF-κB). The compound's ability to scavenge free radicals can be assessed using cell-free antioxidant assays such as DPPH or ABTS radical scavenging assays.
|
| Cell Assay |
Cellular assays for Cyclocurcumin would involve treating relevant cell lines (e.g., macrophages, cancer cells) with the compound and measuring effects on inflammation, oxidative stress, and cell viability. Readouts may include inhibition of pro-inflammatory cytokine production (e.g., TNF-α, IL-6, IL-1β), reduction of reactive oxygen species (ROS), and inhibition of cancer cell proliferation and induction of apoptosis.
|
| Animal Protocol |
In vivo efficacy of Cyclocurcumin would be evaluated in animal models of inflammation, cancer, and other diseases. The compound could be administered orally or via injection, and its effects on disease progression, inflammatory markers, and other relevant endpoints would be assessed. Specific in vivo data for Cyclocurcumin is not detailed in the provided literature. Further studies are needed to evaluate its therapeutic potential.
|
| ADME/Pharmacokinetics |
Cyclocurcumin has a molecular weight of 368.4 and a molecular formula of C21H20O6. It is a minor curcuminoid found in turmeric rhizomes. The compound is a cyclic derivative of curcumin with a distinct structure. It is supplied as a research compound with a purity of ≥95%. The compound should be stored under recommended conditions. It is for research use only and is not intended for human therapeutic use.
|
| Toxicity/Toxicokinetics |
No specific toxicity data is available for Cyclocurcumin in the provided literature. As a naturally occurring curcuminoid, it is generally considered to have low toxicity. However, its safety profile has not been systematically evaluated. Standard preclinical safety studies would be required to evaluate its safety for potential therapeutic applications. The compound is for research use only and is not intended for human therapeutic use.
|
| References |
|
| Additional Infomation |
Cyclocurcumin is a diarylheptane compound.
Cyclocurcumin is a minor curcuminoid found in turmeric rhizomes. It has the same molecular formula as curcumin (C21H20O6) but a significantly different structure. Cyclocurcumin has been studied for its potent anti-inflammatory, antioxidant, and anticancer properties. It is believed to be more stable than curcumin, making it a promising candidate for therapeutic applications. It has a molecular weight of 368.4 and is a research compound not approved for clinical use. |
| Molecular Formula |
C21H20O6
|
|---|---|
| Molecular Weight |
368.38
|
| Exact Mass |
368.126
|
| CAS # |
153127-42-5
|
| PubChem CID |
69879809
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.742
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
27
|
| Complexity |
571
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=C(C=CC(=C1)/C=C/C2=CC(=O)CC(O2)C3=CC(=C(C=C3)O)OC)O
|
| InChi Key |
IZLBLUIBVMGMIY-ZZXKWVIFSA-N
|
| InChi Code |
InChI=1S/C21H20O6/c1-25-20-9-13(4-7-17(20)23)3-6-16-11-15(22)12-19(27-16)14-5-8-18(24)21(10-14)26-2/h3-11,19,23-24H,12H2,1-2H3/b6-3+
|
| Chemical Name |
2-(4-hydroxy-3-methoxyphenyl)-6-[(E)-2-(4-hydroxy-3-methoxyphenyl)ethenyl]-2,3-dihydropyran-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7146 mL | 13.5729 mL | 27.1459 mL | |
| 5 mM | 0.5429 mL | 2.7146 mL | 5.4292 mL | |
| 10 mM | 0.2715 mL | 1.3573 mL | 2.7146 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
